Crossject, a specialty pharmaceutical company in the advanced clinical and regulatory development phase of ZEPIZURE®, an emergency treatment for the management of epileptic seizures based on the award-winning ZENEO® needle-free auto-injector, announces the success of its increase in capital with maintenance of preferential subscription rights for a gross amount of approximately 8 million euros, as announced on April 30, 2024, and a net amount of approximately 7.6 million euros. This financing is an important step in the continued development and registration of ZEPIZURE® and in the establishment of activities in the United States in anticipation of its direct commercialization. The operation was carried out at a subscription price of 1.848 euros, a discount of 10% compared to the closing price on April 30, 2024.
“We are very satisfied with the results of our capital increase and also grateful for the participation of all our shareholders, in particular Gemmes Venture who has supported us with unfailing loyalty since our creation. The irreducible and reducible requests were sufficient to cover the maximum amount of our operation. We sincerely thank those who were unable to be served for their genuine interest and hope that future market opportunities will allow them to add to our shareholder base. ” declared Patrick Alexandre, Chairman of the Board of Directors of Crossject.